Floatz logo

Cetuximab

Salivary Gland Cancer

Fox Chase Cancer Centermonoclonal_antibodyPhase 1/2Dormant
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
51/ 100
Competitive Position
95/ 100

Competitive context

9 Active assets in the Salivary Gland Cancer cohort.

Asset / SponsorPhaseRating
Carboplatin
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2BB
Trastuzumab
Genentech, Inc.
Phase 2BB
Pembrolizumab
OncoC4, Inc.
Phase 2B
Irinotecan
AIDS Malignancy Consortium
Phase 1/2B
Goserelin
National Cancer Center Hospital East
Phase 2B

View all 42 →

Same molecule, other indications

Cetuximab is also rated in:

colon adenocarcinomaActive
BB
Indicative · Phase 3
70 / 100
View asset →
rectal carcinomaActive
BB
Indicative · Phase 2
69 / 100
View asset →
non-small cell lung carcinomaActive
BB
Indicative · Phase 3
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →